We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
-4.37%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$522M
AUM Growth
-$120M
(-19%)
Cap. Flow
-$60.3M
Cap. Flow
% of AUM
-11.56%
Top 10 Holdings %
Top 10 Hldgs %
58.05%
Holding
42
New
7
Increased
15
Reduced
8
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$16.4M |
| 2 |
KALV
KalVista Pharmaceuticals
KALV
|
+$15.6M |
| 3 |
MRUS
Merus
MRUS
|
+$14.5M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$13.5M |
| 5 |
Voyager Therapeutics
VYGR
|
+$13.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$44.7M |
| 2 |
Apogee Therapeutics
APGE
|
+$26.6M |
| 3 |
JBIO
Jade Biosciences
JBIO
|
+$26.2M |
| 4 |
AnaptysBio
ANAB
|
+$22.2M |
| 5 |
Insmed
INSM
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
TScan Therapeutics
TCRX
$48.6M
| $5.5M | 1.05% |
+940,831
| New | +$7.41M |
|
27
VistaGen Therapeutics
VTGN
$9.89M
| $5.32M | 1.02% |
1,529,338
-329,397
| -18% | -$1.43M |
|
|
BBOT
28
BridgeBio Oncology
BBOT
$648M
| $5.11M | 0.98% |
500,000
| – | – |
|
29
Puma Biotechnology
PBYI
$404M
| $4.85M | 0.93% |
1,486,544
+142,916
| +11% | +$627K |
|
30
Kyverna Therapeutics
KYTX
$444M
| $3.74M | 0.72% |
499,152
+349,152
| +233% | +$5.33M |
|
31
Spyre Therapeutics
SYRE
$8.54B
| $3.16M | 0.61% |
134,612
+9,612
| +8% | +$324K |
|
|
32
AnaptysBio
ANAB
$1.58B
| $627K | 0.12% |
25,000
-951,981
| -97% | -$22.2M |
|
33
Lexicon Pharmaceuticals
LXRX
$1.03B
| $50.4K | 0.01% |
+30,000
| New | +$53.8K |
|
|
34
Apogee Therapeutics
APGE
$10.1B
| – | – |
-400,000
| Closed | -$26.6M |
|
35
Arvinas
ARVN
$518M
| – | – |
-71,113
| Closed | -$2.94M |
|
|
JBIO
36
Jade Biosciences
JBIO
$1.2B
| – | – |
-25,363
| Closed | -$26.2M |
|
37
Immunocore
IMCR
$1.72B
| – | – |
-115,000
| Closed | -$7.47M |
|
|
DFTX
38
Definium Therapeutics
DFTX
$5.78B
| – | – |
-2,000,000
| Closed | -$18.8M |
|
39
Ocular Therapeutix
OCUL
$1.79B
| – | – |
-1,728,723
| Closed | -$15.7M |
|
40
Xenon Pharmaceuticals
XENE
$6.06B
| – | – |
-456,148
| Closed | -$19.6M |
|
|
ITCI
41
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-150,000
| Closed | -$10.4M |
|
|
ALPN
42
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-1,128,499
| Closed | -$44.7M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q2 2024 Portfolio in Review
As of Q2 2024, Great Point Partners held 42 positions worth $522M, down 19% from $642M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Great Point Partners withdrew a net $60.3M in Q2 2024, closing 9 positions and reducing 8 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $44.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Great Point Partners opened a new position in KalVista Pharmaceuticals worth $15.8M.
- Great Point Partners's largest Q2 2024 buy was KalVista Pharmaceuticals: 1,338,568 shares worth $15.8M.
- Great Point Partners added most to Cytokinetics in Q2 2024, an estimated $16.4M increase.
- Great Point Partners's biggest Q2 2024 reduction was AnaptysBio, cutting an estimated $22.2M.
- Great Point Partners fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $44.7M.
- Great Point Partners's ten largest holdings make up 58% of its $522M portfolio in Q2 2024.
- Great Point Partners opened 7 new positions and closed 9 in Q2 2024.
- Great Point Partners's portfolio value fell 19% quarter-over-quarter to $522M.
Based on Great Point Partners's 13F filing for Q2 2024, filed 14 Aug 2024.